Compare THRY & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | LUCD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 192.9M |
| IPO Year | 2020 | 2021 |
| Metric | THRY | LUCD |
|---|---|---|
| Price | $1.15 | $0.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | 541.4K | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $785,015,000.00 | $4,346,000.00 |
| Revenue This Year | N/A | $33.93 |
| Revenue Next Year | N/A | $165.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $1.18 | $0.47 |
| 52 Week High | $12.57 | $1.63 |
| Indicator | THRY | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 21.60 | 18.21 |
| Support Level | N/A | N/A |
| Resistance Level | $4.22 | $1.09 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.12 | 1.29 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.